Global Newborn Screening for SMA and SCID Supply, Demand and Key Producers, 2026-2032
Description
The global Newborn Screening for SMA and SCID market size is expected to reach $ 392 million by 2032, rising at a market growth of 11.2% CAGR during the forecast period (2026-2032).
Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.
Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections.
Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons—nerve cells in the brain stem and spinal cord that control essential skeletal muscle activity such as speaking, walking, breathing, and swallowing, leading to muscle weakness and atrophy.
Global key players providing newborn screening for SMA and SCID are Perkinelmer, Thermo Fisher, ImmunoIVD, and Labsystems Diagnostics. The top four companies together hold 90% of the market share, with the largest vendor being Perkinelmer with 60% of the market share. The global companies providing newborn SMA and SCID screening are mainly located in North America and Europe, with North America holding the largest market share with 60%. In terms of product categories, kits dominate the market with 60% market share, followed by instruments and software with 35% and 5% market share, respectively. In terms of applications, SCID screening holds a 65% market share, while SMA screening is 35%.
This report studies the global Newborn Screening for SMA and SCID demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Newborn Screening for SMA and SCID, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Newborn Screening for SMA and SCID that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Newborn Screening for SMA and SCID total market, 2021-2032, (USD Million)
Global Newborn Screening for SMA and SCID total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Newborn Screening for SMA and SCID total market, key domestic companies, and share, (USD Million)
Global Newborn Screening for SMA and SCID revenue by player, revenue and market share 2021-2026, (USD Million)
Global Newborn Screening for SMA and SCID total market by Type, CAGR, 2021-2032, (USD Million)
Global Newborn Screening for SMA and SCID total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Newborn Screening for SMA and SCID market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Perkinelmer, Thermo Fisher, ImmunoIVD, Labsystems Diagnostics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Newborn Screening for SMA and SCID market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Newborn Screening for SMA and SCID Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Newborn Screening for SMA and SCID Market, Segmentation by Type:
Instruments
Kits
Software
Global Newborn Screening for SMA and SCID Market, Segmentation by Application:
SCID Screening
SMA Screening
Companies Profiled:
Perkinelmer
Thermo Fisher
ImmunoIVD
Labsystems Diagnostics
Key Questions Answered
1. How big is the global Newborn Screening for SMA and SCID market?
2. What is the demand of the global Newborn Screening for SMA and SCID market?
3. What is the year over year growth of the global Newborn Screening for SMA and SCID market?
4. What is the total value of the global Newborn Screening for SMA and SCID market?
5. Who are the Major Players in the global Newborn Screening for SMA and SCID market?
6. What are the growth factors driving the market demand?
Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.
Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections.
Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons—nerve cells in the brain stem and spinal cord that control essential skeletal muscle activity such as speaking, walking, breathing, and swallowing, leading to muscle weakness and atrophy.
Global key players providing newborn screening for SMA and SCID are Perkinelmer, Thermo Fisher, ImmunoIVD, and Labsystems Diagnostics. The top four companies together hold 90% of the market share, with the largest vendor being Perkinelmer with 60% of the market share. The global companies providing newborn SMA and SCID screening are mainly located in North America and Europe, with North America holding the largest market share with 60%. In terms of product categories, kits dominate the market with 60% market share, followed by instruments and software with 35% and 5% market share, respectively. In terms of applications, SCID screening holds a 65% market share, while SMA screening is 35%.
This report studies the global Newborn Screening for SMA and SCID demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Newborn Screening for SMA and SCID, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Newborn Screening for SMA and SCID that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Newborn Screening for SMA and SCID total market, 2021-2032, (USD Million)
Global Newborn Screening for SMA and SCID total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Newborn Screening for SMA and SCID total market, key domestic companies, and share, (USD Million)
Global Newborn Screening for SMA and SCID revenue by player, revenue and market share 2021-2026, (USD Million)
Global Newborn Screening for SMA and SCID total market by Type, CAGR, 2021-2032, (USD Million)
Global Newborn Screening for SMA and SCID total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Newborn Screening for SMA and SCID market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Perkinelmer, Thermo Fisher, ImmunoIVD, Labsystems Diagnostics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Newborn Screening for SMA and SCID market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Newborn Screening for SMA and SCID Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Newborn Screening for SMA and SCID Market, Segmentation by Type:
Instruments
Kits
Software
Global Newborn Screening for SMA and SCID Market, Segmentation by Application:
SCID Screening
SMA Screening
Companies Profiled:
Perkinelmer
Thermo Fisher
ImmunoIVD
Labsystems Diagnostics
Key Questions Answered
1. How big is the global Newborn Screening for SMA and SCID market?
2. What is the demand of the global Newborn Screening for SMA and SCID market?
3. What is the year over year growth of the global Newborn Screening for SMA and SCID market?
4. What is the total value of the global Newborn Screening for SMA and SCID market?
5. Who are the Major Players in the global Newborn Screening for SMA and SCID market?
6. What are the growth factors driving the market demand?
Table of Contents
75 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Newborn Screening for SMA and SCID Companies Competitive Analysis
- 4 United States VS China VS Rest of World (by Headquarter Location)
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
